Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.

Authors :: Pulczynski EJ
Simonsen MR
Kuittinen O
Fagerli UM
Erlanson M
Fluge Ø
Leppä S
Østenstad B
Fosså A
Eriksson M
El-Galaly T
Kuitunen H
Papworth K
Ljungqvist M
Pedersen MB
Pollari M
Source :: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2359-2363. Date of Electronic Publication: 2024 Jul 01.
Publication Year :: 2024

Subjects :: Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Antineoplastic Agents, Alkylating therapeutic use
Antineoplastic Agents, Alkylating adverse effects
Cancer Survivors
Dacarbazine therapeutic use
Dacarbazine administration & dosage
Follow-Up Studies
Lymphoma drug therapy
Lymphoma mortality
Maintenance Chemotherapy
Treatment Outcome
Central Nervous System Neoplasms drug therapy
Central Nervous System Neoplasms mortality
Temozolomide therapeutic use

Full Text Access

Tools